CVM150

Phase 1Biologic

CCyanVac LLC

CVM150 is one of 4 biologic programs targeting Vaccines. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VaccinesActive, not recruiting

VaccinesPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Vaccines

#DrugCompanyPhaseTrials

BCG Vaccine

GGynecologic Oncology Group

Phase 3

2 2

Measles Vaccine

GSK

Phase 3

1 3

CVM150

CCyanVac LLC

Phase 1

1 4

Fluenz Tetra

PPublic Health England

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Vaccines

NCT06967181

Clinical

Trials by Indication[1]

Vaccines1 trial

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

Active, not recruiting·CCyanVac LLC·Phase 1·NCT06967181·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CVM150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CVM150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CVM150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CyanVac LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCyanVac LLC

CVM150

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Vaccines1 trial

References

Drug Info

Quick Facts

Related News